Report Open Access

Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review

Isabelle Boutron; Anna Chaimani; Declan Devane; Joerg J Meerpohl; David Tovey; Asbjørn Hróbjartsson; Philippe Ravaud; Gabriel Rada; Giacomo Grasselli


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Covid-19</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">2019-nCoV</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">SARS-CoV-2</subfield>
  </datafield>
  <controlfield tag="005">20200622221822.0</controlfield>
  <controlfield tag="001">3903347</controlfield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Université de Paris, Inserm, Cochrane France, AP-HP, France</subfield>
    <subfield code="0">(orcid)0000-0003-2828-6832</subfield>
    <subfield code="a">Anna Chaimani</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Evidence Synthesis Ireland &amp; Cochrane Ireland, National University of Ireland, Galway, Ireland</subfield>
    <subfield code="0">(orcid)0000-0002-9393-7075</subfield>
    <subfield code="a">Declan Devane</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Institute for Evidence in Medicine, Medical Center &amp; Faculty of Medicine, University of Freiburg and Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany</subfield>
    <subfield code="0">(orcid)0000-0002-1333-5403</subfield>
    <subfield code="a">Joerg J Meerpohl</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Université de Paris, Inserm, Cochrane France, AP-HP, France</subfield>
    <subfield code="a">David Tovey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark and Odense University Hospital, Denmark</subfield>
    <subfield code="a">Asbjørn Hróbjartsson</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Université de Paris, Inserm, Cochrane France, AP-HP, France</subfield>
    <subfield code="0">(orcid)0000-0001-8264-9206</subfield>
    <subfield code="a">Philippe Ravaud</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Epistemonikos Foundation, UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Católica de Chile, Santiago, Chile</subfield>
    <subfield code="a">Gabriel Rada</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy</subfield>
    <subfield code="a">Giacomo Grasselli</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">1370964</subfield>
    <subfield code="z">md5:058e531ba7439f2e210b5370ed1d206f</subfield>
    <subfield code="u">https://zenodo.org/record/3903347/files/Covid-19 NMA protocol update 17-06-2020.pdf</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2020-06-17</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="p">user-covid-19</subfield>
    <subfield code="p">user-covid-nma</subfield>
    <subfield code="p">user-zenodo</subfield>
    <subfield code="o">oai:zenodo.org:3903347</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Université de Paris, Inserm, Cochrane France, AP-HP, France</subfield>
    <subfield code="0">(orcid)0000-0002-5263-6241</subfield>
    <subfield code="a">Isabelle Boutron</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-covid-19</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-covid-nma</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-zenodo</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/legalcode</subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;WHO declared COVID-19 a pandemic on March 11, 2020.&amp;nbsp;Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.&lt;/p&gt;

&lt;p&gt;To this end, we will perform a living mapping of registered randomized trials and a living systematic review&amp;nbsp;with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).&lt;/p&gt;

&lt;p&gt;This protocol details the process and methods we will use.&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isVersionOf</subfield>
    <subfield code="a">10.5281/zenodo.3744599</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5281/zenodo.3903347</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">report</subfield>
  </datafield>
</record>
2,762
1,535
views
downloads
All versions This version
Views 2,762632
Downloads 1,535300
Data volume 2.0 GB411.3 MB
Unique views 2,412558
Unique downloads 1,348281

Share

Cite as